Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGDN: NAC and Silibin for Diabetic Nephropathy
NCT01265563Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2011
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acetylcysteine, silibinin in diabetic nephropathy (DN), sponsored by VA Office of Research & Development. Started Jan 2011; status: completed.
02
Drugs
acetylcysteinesilibinin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01265563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265563.